DOCSLIB.ORG

Drug and Medication Classification Schedule

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine Epibatidine Gepirone Amyl nitrite Butaperazine Conorphone Epinephrine Gestrinone Anileridine Butoctamide Conotoxin Ergaloid Mesylates Glutethimide Anilopam Calusterone Corticaine Erthritol tetranitrate Guanadrel Apomorphine Camazepam Crotetamide Erythropoietin Guanethidine Aprobarbital Cannabinoids, Cyamemazine Eszopiclone Halazepam Arecoline Synthetic Cyclandelate Estazolam Haloperidol Atracurium Captadiame Cyclobarbital Ethamivan Haloxazolam Atomoxetine Carazolol Darbepoetin Ethanol Hemoglobinglutamers Azacylonol Carbidopa Decamethonium Ethchlorvynol Hemopure Azaperone Carbromal Dehydrochloromethy- Ethinamate Hexafluorenium Barbital Carfentanil testosterone Ethoheptazine Hexobarbital Barbiturates Carphenazine Delorazepam Ethopropazine Homophenazine Bemegride Carpipramine Demoxepam Ethosuximide Hydrocodone Benazepril Cathinone Dermorphin Ethylisobutrazine Hydromorphone Benperidol Chloral betaine Desipramine Ethylmorphine Hydroxyamphetamine Bentazepam Chloral hydrate Desoxymethyl- Ethylnorepinephrine Ibomal Benzactizine Chloraldehyde testosterone Ethylphenidate Iloprost Benzoctamine Chloralose Dextromoramide Etidocaine Imipramine Benzonatate Chlordiazepoxide Dezocine Etifoxin Inositol Benzphetamine Chlorhexadol Diamorphine Etizolam Trispyrophosphate Benztropine Chlormezanone Dichloralphenazone Etodroxizine Ipsapirone Benzylpiperazine Chloroform Diethylpropion Etomidate Irbesarten Bethanidine Chloroprocaine Diethylthiambutene Etorphine HCL Isocarboxazid Biperiden Chlorproethazine Dihydrocodeine Fenarbamate Isomethadone Biriperone Chlorpromazine Dimefline Fenfluramine Isoproterenol Bitolterol Chlorprothixene Diprenorphine Fentanyl Ketazolam Page 1 of 6 Ketorolac 3-Methoxytyramine Paliperidone Propofol Thialbarbital Lamotrigine Methyl-1-testosterone Pancuronium Propoxycaine Thiamylal Lenperone Methylandriostenediol Papaverine Prostanozol Thiethylperazine Levodopa Methyldienolone Paraldehyde Prothipendyl Thiopental Levomethorphan Methyldopa Paramethadione Protokylol Thiopropazate Levorphanol Methylene Pargyline Protriptyline Thioproperazine Lisinopril Dioxypyrovalene Paroxetine Proxibarbital Thioridazine Lithium (MDPV; 3,4 Pemoline Pyrithyldione Thiothixene Lobeline Methylenedioxy- Penfluridol Quazipam Tiapride Lofentanil pyrovalerone) Pentaerythritol Quetiapine Tiletamine Loflazepate, Ethyl Methylhexaneamine Pentobarbital Quinapril / Quinaprilat Timiperone Loprazolam Methylnortestosterone Pentylenetetrazol Quinbolone Tofisopam Lorazepam Methylphenidate Perazine Racemethorphan Topirimate Lormetazepam Methyprylon Perfluorocarbons Racemorphan Torsemide Loxapine Metocurine Perfluorodecahydro- Raclopride Tranylcypromine Mabuterol Metomidate naphthalene Ractopamine Trazodone Maprotiline Metopon Perfluorodecalin Ramipril / Ramiprilat Tretoquinol Mazindol Mexazolam Perfluorooctylbromide Remifentanil Triazolam Mebutamate Mirtazapine Perfluorotripro- Remoxipride Tribromethanol Meclofenoxate Mivacurium pylamine Rilmazafone Tricaine Medazepam Modafinil Periciazine Risperidone Trichloroethanol Meldonium Molindone Perindopril Ritanserin Tricholoethylene Melperone Moperone Perlapine Rivastigmine Triclofos Memantine Morphine Perphenazine Rocuronium Trifluomeprazine Meparfynol Mosapramine Phenaglycodol Ropivacaine Trifluoperazine Mepazine Muscarine Phenazocine Secobarbital Trifluperidol Meperidine Naepaine Phencyclidine Selegiline Triflupromazine Mephenoxalone Nalbuphine Phendimetrazine Sertraline Trihexylphenidyl Mephentermine Nalorphine Phenelzine Sildenafil Trimethaphan Mephenytoin Nebivolol Phenmetrazine Snake Venoms Trimipramine Mephobarbital Nefazodone Phenobarbital Somatrem Tubocurarine Meprobamate Nefopam Phentermine Somatropin Tybamate Mesoridazine Nikethamide Physostigmine Spiclomazine Urethane Mestanolone Nimetazepam Picrotoxin Spiperone Valerenic Acid Mesterolone Nitrazepam Piminodine Spirapril / Spiraprilat Valnoctamide Metaclazepam Norbolethone Pimozide Stenbolone Vardenafil Metaraminol Norclostebol Pinazepam Succinylcholine Venlafaxine Metazocine Nordiazepam Pipamperone Sufentanil Veralipride Methachloline Norepinephrine Pipecuronium Sulfondiethylmethane Vercuronium Methadone Norethandrolone Pipequaline Sulfonmethane Viloxazine Methamphetamine* Nortriptyline Piperacetazine Sulforidazine Vinbarbital Methandriol Nylidrin Piperocaine Sulpiride Vinylbital Methandrostenolone Olanzapine Pipotiazine Sultopride Zaleplon Methaqualone Olmesartan Pipradrol Tadalasil Ziconotide Metharbital OxaboloneOxazepam Piquindone Talbutal Zilpaterol Methasterone Oxazolam Piritramide Tandospirone hydrochloride Methcathinone Oxcarbazepine Prazepam Temazepam Ziprasidone Methenolone Oxilofrine Procaterol Terazosin Zolazepam Methixene Oxprenolol Prochlorperazine Tetrabenazine Zolpidem Methohexital Oxycodone Propanidid Tetracaine Zopiclone Methotrimeprazine Oxymesterone Propiomazine Tetrahydrogestrinone Zotepine Methoxamine Oxymorphone Propionylpromazine Tetrazepam Zuclopenthixol Methoxyphenamine Oxypertine Propiram Thebaine * When detected as exclusively l-methamphetamine refer to Class B Drugs penalty schedule. When d-methamphetamine is detected alone, or in combination with l- methamphetamine, Class A penalty schedule applies. Page 2 of 6 Class B drugs, medications, and substances are those (1) that are approved by the United States Food and Drug Administration and have a high potential to influence performance in the equine athlete but less potential than Class A drugs, medications, and substances that are classified at that level because they have the highest potential to influence performance, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class C drugs, medications, or substances that are approved by the United States Food and Drug Administration. 2-Aminoheptane Carteolol Etodolac Mepenzolate Pergolide Acebutolol Carticaine Felbamate Mephenesin Phenacemide Acepromazine Carvedilol Felodipine Mepivacaine Phenoxybenzamine Acetanilid Celecoxib Fenbufen Meralluride Phensuximide Acetophenetidin Chlormerodrin Fenclozic acid Merbaphen Phentolamine Adrenochrome Chlorothiazide Fenoldopam Mercaptomerin Phenylephrine monosemicarbazone Chlorpheniramine Fenoprofen Mercumatilin Phenylpropanolamine salicylate Chlorthalidone Fenoterol Mersalyl Phenytoin Albuterol Chlorzoxazone Fenspiride Metaproterenol Pindolol Alclofenac Cilostazol Fentiazac Metaxalone Pirbuterol Aldosterone Clanobutin Flecainide Methantheline Piretanide Ambenonium Clemastine Floctafenine Methapyrilene Piroxicam Ambroxol Clenbuterol Flufenamic acid Methdilazine Polythiazide Amiloride Clidinium Flumethiazide MethosuxamideMetho Prazosin Aminophylline Clofenamide Flunarizine trexate Prilocaine Aminopyrine Clonidine Fluoroprednisolone Methscopolamine Primidone Amiodarone Colchicine Fluoxymesterone Methylatropine Procainamide Amisometradine Cyclizine Fluphenazine Methylchlorthiazide Procaine Amitraz Cyclobenzaprine Flurbiprofen Methysergide Procyclidine Amlodipine Cyclothiazide Formoterol Methyltestosterone Promazine Amrinone Cycrimine Fosphenytoin Metiamide Promethazine Anisotropine Cyproheptadine Gabapentin Metolazone Propafenone Antipyrine Danazol Guanabenz Metoprolol Propantheline Apazone Deracoxib Heptaminol Mexilitine Propentophylline Aprindine Detomidine Hexocyclium Mibefradil Propranolol Arformoterol Dextromethorphan Hexylcaine Mibolerone Propylhexedrine Articaine Dextropropoxyphene Homatropine Midazolam Pseudoephedrine Atenolol Diazepam Hydralazine Midodrine Pyridostigmine Atropine Diazoxide Hydrochlorthiazide Milrinone Pyrilamine Baclofen Dibucaine Hydroflumethiazide Minoxidil Quinidine Bendroflumethiazide Diflunisal Hydroxyzine Moexipril Reserpine Benoxaprofen Digitoxin Ibutilide Nadol Ritodrine Benzocaine Digoxin Indomethacin Naloxone Rizatriptan Benzthiazide Dihydroergotamine Infliximab Naltrexone Rofecoxib Bepridil Diltiazem Ipratropium Nandrolone Romifidine Betaxolol Dimethisoquin Isoetharine Naphazoline Salmeterol Bisoprolol Diphenhydramine Isometheptene Naratriptan Scopolamine
Recommended publications
  • Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library

    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    The Anxiomimetic Properties of Pentylenetetrazol in the Rat

    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
  • Understanding Benzodiazephine Use, Abuse, and Detection

    Understanding Benzodiazephine Use, Abuse, and Detection

    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
  • Withdrawing Benzodiazepines in Primary Care

    Withdrawing Benzodiazepines in Primary Care

    PC\/ICU/ ADTiriC • CNS Drugs 2009,-23(1): 19-34 KtVltW MKIIWLC 1172-7047/I»/O(X)1«119/S4W5/C1 © 2009 Adis Dato Intocmation BV. All rights reserved. Withdrawing Benzodiazepines in Primary Care Malcolm Luder} Andre Tylee^ and ]ohn Donoghue^ 1 Institute of Psychiatry, King's College London, London, England 2 John Moores University, Liverpool, Scotland Contents Abstract ' 19 1. Benzodiazepine Usage 22 2. Interventions 23 2.1 Simple interventions 23 2.2 Piiarmacoiogicai interventions 25 2.3 Psychoiogical Interventions 26 2.4 Meta-Anaiysis ot Various interventions 27 3. Outcomes 28 4. Practicai Issues 29 5. Otiier Medications 30 5.1 Antidepressants 30 5.2 Symptomatic Treatments 30 6. Conciusions 31 Abstract The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinua- tion is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addic- tion have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescdbers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discon- tinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescdbers.
  • GABA Receptors

    GABA Receptors

    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
  • Atomoxetine: a New Pharmacotherapeutic Approach in the Management of Attention Deficit/Hyperactivity Disorder

    Atomoxetine: a New Pharmacotherapeutic Approach in the Management of Attention Deficit/Hyperactivity Disorder

    i26 Arch Dis Child: first published as 10.1136/adc.2004.059386 on 21 January 2005. Downloaded from Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder J Barton ............................................................................................................................... Arch Dis Child 2005;90(Suppl I):i26–i29. doi: 10.1136/adc.2004.059386 Atomoxetine is a novel, non-stimulant, highly selective lifespan including a potential requirement for lifelong treatment.4 Because of the limitations of noradrenaline reuptake inhibitor that has been studied for existing treatments and the paradigm shift in use in the treatment of attention deficit/hyperactivity thinking about the management of ADHD, there disorder (ADHD). Data from clinical trials show it to be well is an interest in the development of new pharmacological treatments. tolerated and effective in the treatment of ADHD in children, adolescents, and adults. Improvements were seen ATOMOXETINE HYDROCHLORIDE: A not only in core symptoms of ADHD, but also in broader NOVEL TREATMENT FOR ADHD social and family functioning and self esteem. Once-daily Atomoxetine is the first non-stimulant to be approved for the treatment of ADHD and the first dosing of atomoxetine has been shown to be effective in drug to be licensed for the treatment of ADHD in providing continuous symptom relief. Atomoxetine does adults.5 Atomoxetine was licensed in the US in not appear to have abuse potential and is associated with November 2002 and in the UK in May 2004. At the time of writing, it is under consideration for a benign side effect profile. The development of licensing by the regulatory authorities in a atomoxetine thus represents an important advance in the number of other countries.
  • <I>Iguana Iguana</I>

    <I>Iguana Iguana</I>

    Journal of the American Association for Laboratory Animal Science Vol 58, No 6 Copyright 2019 November 2019 by the American Association for Laboratory Animal Science Pages 810–816 Use of Rodent Sedation Tests to Evaluate Midazolam and Flumazenil in Green Iguanas (Iguana iguana) Thais F Bressan, Thayanee Sobreira, and Adriano B Carregaro* This study aimed to evaluate the applicability of rodent behavioral tests to assess the effects of midazolam and flumazenil in green iguanas. Four tests commonly used to assess sedation in rodents—the open field test, forced swim test, behavioral scale, and traction test—were conducted in 10 juveniles iguanas. The animals received midazolam (2 mg/kg IM) or 0.9% NaCl (0.4 mL/kg IM), and the tests were conducted between 0 and 300 min thereafter. To verify the effects of midazolam and flumazenil, the most informative tests from the evaluation stage and the limb withdrawal latency time (LWLT) were used. All 10 iguanas were tested under 4 conditions, as follows: MS, midazolam (2 mg/kg IM), followed 30 min later by 0.9% NaCl (0.4 mL/kg IM); FS, flumazenil (0.05 mg/kg IM), followed by 0.9% NaCl (0.4 mL/kg IM) 30 min later; MF, midazolam (2 mg/ kg IM), followed by flumazenil (0.05 mg/kg IM) 30 min later; and CON, 0.9% NaCl (0.4 mL/kg IM). The behavioral scale and the forced swim test showed the best detection of the onset, peak effect, and the differences between the sedated and con- trol iguanas, with testing done between 15 and 240 min after drug administration.
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al

    United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al

    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis

    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
  • STRATTERA Safely and Effectively

    STRATTERA Safely and Effectively

    1 HIGHLIGHTS OF PRESCRIBING INFORMATION serious cardiac problems that may place them at increased These highlights do not include all the information needed to use vulnerability to its noradrenergic effects. Consideration should be STRATTERA safely and effectively. See full prescribing given to not using STRATTERA in adults with clinically significant information for STRATTERA. cardiac abnormalities. (5.3) ® • Emergent Cardiovascular Symptoms – Patients should undergo STRATTERA (atomoxetine) capsules, for oral use prompt cardiac evaluation. (5.3) Initial U.S. Approval: 2002 • Effects on Blood Pressure and Heart Rate – Increase in blood WARNING: SUICIDAL IDEATION IN CHILDREN AND pressure and heart rate; orthostasis and syncope may occur. Use ADOLESCENTS with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. (5.4) See full prescribing information for complete boxed warning. • Emergent Psychotic or Manic Symptoms – Consider discontinuing • Increased risk of suicidal ideation in children or adolescents treatment if such new symptoms occur. (5.5) (5.1) • Bipolar Disorder – Screen patients to avoid possible induction of a • No suicides occurred in clinical trials (5.1) mixed/manic episode. (5.6) • Aggressive behavior or hostility should be monitored. (5.7) • Patients started on therapy should be monitored closely (5.1) • Possible allergic reactions, including anaphylactic reactions, angioneurotic edema, urticaria, and rash. (5.8) ------------------------INDICATIONS AND USAGE------------------------------- • Effects on Urine Outflow – Urinary hesitancy and retention may STRATTERA® is a selective norepinephrine reuptake inhibitor occur. (5.9) indicated for the treatment of Attention-Deficit/Hyperactivity Disorder • Priapism – Prompt medical attention is required in the event of (ADHD). (1.1) suspected priapism. (5.10, 17) • Growth – Height and weight should be monitored in pediatric -----------------------DOSAGE AND ADMINISTRATION----------------------- patients.